Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07138274
PHASE2

Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS

Sponsor: Mayo Clinic

View on ClinicalTrials.gov

Summary

single-center, randomized, double-blind, placebo-controlled Phase 2 study to evaluate safety and efficacy of overnight metyrapone in patients with MACS.

Official title: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Metyrapone in Subjects Diagnosed With Mild Autonomous Cortisol Secretion (MACS)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

90

Start Date

2026-04

Completion Date

2031-12

Last Updated

2025-08-22

Healthy Volunteers

No

Interventions

DRUG

Metyrapone 250 mg Oral Tablets

Subjects will receive metyrapone beginning at 500 mg and titrating up to 1000 mg

DRUG

Placebo

Subjects will receive placebo at 500 mg dose and titrated up to 1000 mg to match interventional arm and prevent unblinding